Core Viewpoint - CloudTop New Horizon (01952) saw a significant stock increase of over 5%, closing at 73.35 HKD with a trading volume of 499 million HKD, following the announcement of its core product, Aicromod, being included in the 2025 ACG Clinical Guidelines for Ulcerative Colitis [1] Group 1: Product Development and Recognition - Aicromod has been strongly recommended for the induction and maintenance treatment of moderate to severe active Ulcerative Colitis (UC) patients in the newly released guidelines [1] - The product was previously included in the 2024 American Gastroenterological Association (AGA) clinical practice guidelines as a first-line treatment for Ulcerative Colitis, highlighting its clinical value and potential to fill treatment gaps [1] Group 2: Strategic Investments - CloudTop New Horizon announced a strategic investment of 30.9 million USD in Tianjing Bio, increasing its ownership stake to 16.1%, making it the largest shareholder [1] - According to CMB International, this strategic investment allows the company to leverage Tianjing's differentiated 4-1BB platform, dual antibody pipeline, and overseas clinical transformation capabilities, creating synergies with its existing mRNA tumor vaccine portfolio [1]
港股异动 云顶新耀(01952)尾盘涨超5% 艾曲莫德再获国际指南推荐 公司近期战略投资天境生物